2ccPA Study in Patients With Symptomatic Knee Osteoarthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 13, 2018

Primary Completion Date

March 22, 2021

Study Completion Date

March 22, 2021

Conditions
Osteoarthritis (OA) of the Knee
Interventions
DRUG

2ccPA

"Four dose cohorts (50 μg, 200 μg, 800 μg, and 2,400 μg) are planned in this study sequentially.~study group: one dose intra-articular on day1"

DRUG

placebo

"A total of 8 subjects will be recruited and randomized in each dose cohort with a 3:1 ratio (6 subjects in the 2ccPA treatment arm and 2 subjects in the placebo arm).~control group: one dose intra-articular on day 1"

Trial Locations (5)

112

Veteran General Hospital Taipei, Taipei

114

Tri-Service General Hospital, Taipei

833

Kaohsiung Chang Gung Memorial Hospital, Taipei

25160

Mackay Memorial Hospital, Taipei

Unknown

National Cheng Kung University Hospital, Taipei

All Listed Sponsors
lead

Orient Europharma Co., Ltd.

INDUSTRY

NCT04229394 - 2ccPA Study in Patients With Symptomatic Knee Osteoarthritis | Biotech Hunter | Biotech Hunter